Model with all universally available baseline variables
HR | Lower CI | Upper CI | p Value | |
Sex × digoxin interaction | 1.02 | 0.95 | 1.09 | 0.65 |
Digoxin use | 1.00 | 0.95 | 1.05 | 0.89 |
Female sex | 0.86 | 0.83 | 0.90 | <0.0001 |
Year of CHF diagnosis | 0.99 | 0.98 | 0.99 | <0.0001 |
Age 50–64 years | 0.42 | 0.40 | 0.44 | <0.0001 |
Age 65–74 years | 0.58 | 0.56 | 0.60 | <0.0001 |
Hypertension | 0.91 | 0.88 | 0.94 | <0.0001 |
Stroke | 1.34 | 1.29 | 1.40 | <0.0001 |
MI | 1.15 | 1.11 | 1.20 | <0.0001 |
COPD | 1.36 | 1.30 | 1.43 | <0.0001 |
Fracture | 1.08 | 1.03 | 1.14 | 0.001 |
Diabetes | 1.34 | 1.28 | 1.40 | <0.0001 |
Atrial fibrillation | 0.93 | 0.89 | 0.97 | 0.001 |
Loop diuretic use | 1.27 | 1.23 | 1.32 | <0.0001 |
Potassium-sparing diuretic use | 1.07 | 1.03 | 1.11 | 0.00 |
Thiazide diuretic | 1.03 | 0.99 | 1.07 | 0.16 |
Oral anticoagulant use | 0.92 | 0.87 | 0.98 | 0.001 |
β Blocker use | 0.83 | 0.79 | 0.86 | <0.0001 |
ACE use | 0.97 | 0.93 | 1.00 | 0.07 |
ARB use | 0.90 | 0.82 | 0.98 | 0.01 |
CCB use | 0.93 | 0.90 | 0.97 | 0.001 |
ARB, angiotensin receptor blocker; CCB, calcium channel blocker; COPD, chronic obstructive pulmonary disease; MI, myocardial infarction.